行政院國家科學委員會專題研究計畫成果報告:COMT抑制劑entacapone對於巴金森氏病患者的血清catecholamine濃度及心臟血管系統的影響
Date Issued
2002
Date
2002
Author(s)
�d���
DOI
902314B002246
Abstract
This study is an open label, and single-arm study that will evaluate the changes in the plasma
concentrations of norepinephrine and epinephrine after the co-administration of single dose of
entacapone and L-dopa/AADC inhibitor in PD patients. On the first day of pharmacokinetic
evaluation, patients took only their individual, standard dose of levodopa（Sinemetâ or
Madoparâ）; On the second day, a single dose of entacapone 200 mg was coadministered with
levodopa. Venous blood samples were taken immediately before test dose and at different
time points thereafter within two days. Plasma concentration of plasma concentration of
catecholamine were measured by reverse-phase high-performance liquid chromatography
with electrochemical detector. Moreover, blood pressure and heart rate were measured to
evaluate the safety of entacapone. In the present study, we did not see a significant change
in the heart rate, blood pressure and plasma concentration of catecolamine after the
administration of entacapne, suggesting a well toleration in the hemodynamic system.
Subjects
Parkinson’s disease
entacapone
plasma catecholamine
hemodynamics
Publisher
臺北市：國立臺灣大學醫學院神經科
Type
journal article
File(s)![Thumbnail Image]()
Loading...
Name
902314B002246.pdf
Size
187.54 KB
Format
Adobe PDF
Checksum
(MD5):6a1ec202c5183592444c6bd0ef1de28d